54. Breast Cancer Res Treat. 2018 Jul;170(2):303-312. doi: 10.1007/s10549-018-4733-y.Epub 2018 Mar 10.Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection inclinically node-negative patients with operable breast cancer. Results of theGF-GS01 randomized trial.Roy P(1)(2)(3)(4), Leizorovicz A(5)(6)(7)(8), Villet R(9), MercierC(10)(5)(6)(7), Bobin JY(11).Author information: (1)Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, 162 AvenueLacassagne, 69003, Lyon, France. pascal.roy@chu-lyon.fr.(2)Université de Lyon, Lyon, France. pascal.roy@chu-lyon.fr.(3)Université Lyon 1, Villeurbanne, France. pascal.roy@chu-lyon.fr.(4)Laboratoire de Biométrie et Biologie Évolutive, CNRS, UMR 5558, Villeurbanne, France. pascal.roy@chu-lyon.fr.(5)Université de Lyon, Lyon, France.(6)Université Lyon 1, Villeurbanne, France.(7)Laboratoire de Biométrie et Biologie Évolutive, CNRS, UMR 5558, Villeurbanne, France.(8)Service de pharmacologie clinique et essais thérapeutiques, Hospices Civils deLyon, Bron, France.(9)Service de chirurgie viscérale et gynécologique, Groupe hospitalierDiaconesses-Croix-Saint-Simon, Paris, France.(10)Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, 162Avenue Lacassagne, 69003, Lyon, France.(11)Service de Chirurgie Oncologique, Hospices Civils de Lyon, Pierre-Bénite,France.PURPOSE: Sentinel-lymph-node (SLN) resection seems to minimize systematicaxillary-lymph-node dissection (sALND) side effects in operated breast cancerpatients. We explored whether SLN resection achieves similar therapeutic outcomesas sALND but with fewer side effects.METHODS: A randomized, controlled, open-label trial with parallel-group designcompared sALND restricted to cases with positive SLN biopsy (test arm, n = 774)versus SLN biopsy followed by sALND (control arm, n = 770).RESULTS: The five-year overall survivals in control and test arms were 96.42 and 95.64% (P = 0.2925). The estimated difference was nearly zero (precisely,- 0.79%, one-tailed 95% confidence interval (CI) limit - 2.44%). In amultivariate Cox model, the adjusted hazard ratio in the test arm was HR 0.81(upper 95% CI limit 1.17). Advanced age (HR 1.05 per additional year, CI[1.03-1.08]), negative progesterone receptor (HR 2.17 [1.35-3.45]), SLNmetastasis (HR 1.69 [1.03-2.79]), and only one SLN identification technique (HR4.14 [1.21-14.18]) were associated with lower survival. Patients with ≥ 1 severe side effect at 1 month in control and test arms were 173/703 = 24.6% [21.5-28.0%]and 91/693 = 13.1% [10.7-15.9%] (P < 0.001). The estimated sensitivity of SLNbiopsy (control arm) was 145/178 = 81.5% [74.8-86.7%].CONCLUSIONS: Restricting ALND to cases with positive SLN biopsy does not affectthe overall survival but reduces by 11.5% [7.5-15.6%] (P < 0.001) the risk ofsevere short-time side effects of sALND.DOI: 10.1007/s10549-018-4733-y PMCID: PMC5999168PMID: 29526019 